focus -WSS

focus

author：knowledge 2025-09-30 16:24:52 - browse：83

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Bird flu in dairy cattle: New measures to control spread to humans

entertainment

hotspot

WSS

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Researchers test human milk's ability to repair gut microbiome

Drinking water from half of US faucets contains PFAS: Study

Oral obesity drug from Viking Therapeutics hits key early target

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

California man arrested in connection with serial murders of Mexican strip club workers

entertainment

focus

focus

Sports medicine is finally prioritizing gender equality

Young boy dies in trial for Pfizer Duchenne gene therapy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Drug companies' payments and gifts affect physicians' prescribing

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Neutralizing antibodies against HIV shows promise in children

How one medical school became remarkably diverse

Four alarming medical procedures we’re glad history forgot

Virginia high school admissions case could be legal follow

The PBM ad wars are taking over Washington, D.C.

entertainment

Gut bacteria may contribute to kidney autoimmunity, study finds

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

U.K. decision on ALS drug has neurologists, advocates up in arms

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Study: Black kids more likely to die after surgery than white kids

focus

entertainment

hotspot

knowledge